A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Public ClinicalTrials.gov record NCT06459180. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of this study is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatment for participants with recurrent or metastatic cervical cancer in the Phase 3 portion. The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan results in a superior overall survival compared to TPC in participants with high trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.
Study identification
- NCT ID
- NCT06459180
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 686 participants
Conditions and interventions
Conditions
Interventions
- Sacituzumab Tirumotecan Biological
- Pemetrexed Drug
- Tisotumab Vedotin Biological
- Topotecan Drug
- Vinorelbine Drug
- Gemcitabine Drug
- Irinotecan Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 23, 2024
- Primary completion
- Jun 14, 2028
- Completion
- Jun 14, 2028
- Last update posted
- Aug 27, 2026
2024 – 2028
United States locations
- U.S. sites
- 38
- U.S. states
- 20
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USA Mitchell Cancer Institute-Clinical Trials ( Site 4126) | Mobile | Alabama | 36604 | — |
| Providence Alaska Medical Center ( Site 4137) | Anchorage | Alaska | 99508 | — |
| HonorHealth (HH) ( Site 8002) | Phoenix | Arizona | 85016 | — |
| Arizona Oncology Associates - HOPE ( Site 8001) | Tucson | Arizona | 85711 | — |
| Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 4125) | La Jolla | California | 92093 | — |
| UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4105) | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian ( Site 4104) | Newport Beach | California | 92663 | — |
| Mount Sinai Comprehensive Cancer Center ( Site 4143) | Miami Beach | Florida | 33140 | — |
| Advent Health ( Site 4140) | Orlando | Florida | 32804 | — |
| Florida Cancer Specialists East ( Site 7001) | West Palm Beach | Florida | 33401 | — |
| Northside Hospital ( Site 4127) | Atlanta | Georgia | 30342 | — |
| Georgia Cancer Center at Augusta University ( Site 4112) | Augusta | Georgia | 30912 | — |
| Lewis Cancer and Research Pavilion ( Site 4114) | Savannah | Georgia | 31405 | — |
| University Medical Center New Orleans ( Site 4132) | New Orleans | Louisiana | 70112 | — |
| Willis Knighton Medical Center ( Site 4101) | Shreveport | Louisiana | 71103 | — |
| The Center of Hope ( Site 4106) | Reno | Nevada | 89511 | — |
| Holy Name Medical Center ( Site 4117) | Teaneck | New Jersey | 07666 | — |
| Optimum Clinical Research Group ( Site 4138) | Albuquerque | New Mexico | 87109 | — |
| Perlmutter Cancer Center NYU Langone Hospital - Long Island ( Site 4145) | Mineola | New York | 11501 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 4121) | New York | New York | 10016 | — |
| Duke Cancer Institute ( Site 4120) | Durham | North Carolina | 27710 | — |
| University of Cincinnati Medical Center ( Site 4128) | Cincinnati | Ohio | 45219 | — |
| The Ohio State University ( Site 4103) | Hilliard | Ohio | 43026 | — |
| Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research ( Site 4116) | Tulsa | Oklahoma | 74146 | — |
| Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007) | Eugene | Oregon | 97401 | — |
| Legacy Good Samaritan Medical Center-Oncology Clinical Research ( Site 4115) | Portland | Oregon | 97210 | — |
| Sidney Kimmel Cancer Center - Jefferson Health ( Site 4142) | Philadelphia | Pennsylvania | 19107 | — |
| Asplundh Cancer Pavilion ( Site 4113) | Willow Grove | Pennsylvania | 19090 | — |
| The West Clinic, PLLC dba West Cancer Center ( Site 4108) | Germantown | Tennessee | 38138 | — |
| Texas Oncology - Central/South Texas ( Site 8010) | Austin | Texas | 78731 | — |
| Texas Oncology - DFW ( Site 8003) | Fort Worth | Texas | 76104 | — |
| Houston Methodist Hospital OB/GYN ( Site 4102) | Houston | Texas | 77030 | — |
| Texas Oncology - San Antonio ( Site 8006) | San Antonio | Texas | 78240 | — |
| Texas Oncology - Northeast Texas ( Site 8009) | Tyler | Texas | 75702 | — |
| Texas Oncology - Gulf Coast ( Site 8008) | Webster | Texas | 77598 | — |
| University of Virginia Cancer Center ( Site 4123) | Charlottesville | Virginia | 22908 | — |
| Inova Schar Cancer Institute ( Site 4139) | Fairfax | Virginia | 22031-4867 | — |
| Swedish Medical Center-Swedish Cancer Institute ( Site 4134) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 202 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06459180, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06459180 live on ClinicalTrials.gov.